- ￥376 - 3990
- Solarbio
- 北京
- IL1800
- 2025年07月23日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件：
Powder:2-8℃，2 years;Insolvent(母液):-20℃，6 months;-80℃，1 year
- 保质期：
Powder:2-8℃，2 years;Insolvent(母液):-20℃，6 months;-80℃，1 year
- 英文名：
LY-3009120
- 库存：
现询
- 供应商：
北京索莱宝科技有限公司
- CAS号：
1454682-72-4
- 规格：
50mg/25mg/1mg/10mg/5mg
| 规格： | 50mg | 产品价格： | ￥3990.0 |
|---|---|---|---|
| 规格： | 25mg | 产品价格： | ￥2690.0 |
| 规格： | 1mg | 产品价格： | ￥376.0 |
| 规格： | 10mg | 产品价格： | ￥1340.0 |
| 规格： | 5mg | 产品价格： | ￥840.0 |
| 基本信息 | |
| CAS | No.1454682-72-4 |
| 英文名称 | LY-3009120 |
| 别名 | ;LY3009120;LY-3009120; |
| 分子式 | C23H29FN6O |
| 分子量 | 424.51 |
| 溶解性 | Soluble in DMSO ≥1mg/mL(Need ultrasonic) |
| 纯度 | ≥98% |
| 外观(性状) | Light yellow to brown Solid |
| 储存条件 | Powder:2-8℃，2 years;Insolvent(母液):-20℃，6 months;-80℃，1 year |
| MDL | MFCD28411374 |
| SMILES | O=C(NC1=CC(C2=CC3=CN=C(NC)N=C3N=C2C)=C(C)C=C1F)NCCC(C)(C)C |
| 靶点 | Raf |
| 通路 | MAPK |
| 背景说明 | LY-3009120是一种新型有效的pan-Raf抑制剂。 |
| 生物活性 | LY3009120 (DP-4978) is a pan RAF inhibitor which inhibits BRAFV600E， BRAFWT and CRAFWT with IC50s of 5.8， 9.1 and 15 nM， respectively.[1-4] |
| In Vitro | In the whole-cell based KiNativ assay， LY3009120 shows affinity to each RAF isoform with the IC50 of 44， 31-47 and 42 nM for ARAF， BRAF and CRAF respectively. LY3009120 exhibits anti-proliferative effects on cell lines harboring BRAFV600E， KRASG13 and KRASG12 mutations. LY3009120 (1 μM) inhibits the phosphorylation of both MEK1/2 and ERK1/2 in cell lines with high basal levels of pMEK1/2 and pERK1/2 (RKO and HCT 116)[1]. LY3009120 shows inhibitory effect on tumor cells such as BxPC-3， NCI-H2405 and OV-90 cell lines. LY3009120 (0.01 μM) demonstrates potent and dose-dependent inhibition of phospho-MEK and ERK in all three cell lines. LY3009120 demonstrates a concentration-dependent cell growth inhibition with IC50 values of 0.04， 0.087， and 0.007 μM against H2405， BxPC-3， and OV-90 cells， respectively[2]. LY3009120 inhibits BRAFWT， CRAFWT， BRAFV600E， and BRAFV600E+G468A with the IC50 values of 9.1， 15， 5.8， and 17 nM， respectively. LY3009120 induces BRAF-CRAF dimerization but inhibits the phosphorylation of downstream MEK and ERK. LY3009120 also inhibits various forms of RAF dimers including BRAF or CRAF homodimers[3]. LY3009120 gives only very minor activation at very low doses， with near complete inhibition of phospho-ERK at concentrations above 100 nM[4]. |
| 细胞实验 | LY3009120 (20 mg/kg bid) displays significant activity in in vivo BRAFmut and KRASmut CRC xenograft models. In Colo 205 xenografts (BRAFmut)， LY3009120 results in statistically significant tumor regression， while treatment of HCT 116 xenografts (KRASmut) results in statistically significant inhibition of tumor growth. LY3009120 treatment reduces pMEK1/2 in all HT-29 xenografts and reduces pERK1/2 in the majority of HT-29 xenografts[1]. LY3009120 (15 or 30 mg/kg) achieves almost complete tumor growth regression， and inhibits downstream phospho-MEK and ERK by approximately 70% and 60%， respectively， in the H2405 model[2]. |
| 细胞实验 | Briefly， cells are grown in McCoy’s 5A supplemented with 10% characterized fetal bovine serum at 37°C， 5% CO2， and 95% humidity. Cells are allowed to expand until 75-90% confluency at which point they are subcultured or harvested for assay use. A serial dilution of test compound is dispensed into a 384-well black clear bottom plate in triplicate. Six-hundred-twenty-five cells are added per well in 50 μL of complete growth medium in the 384-well plate. Plates are incubated for 67 h at 37°C， 5% CO2， and 95% humidity. At the end of the incubation period， 10 μL of a 440 μM solution of resazurin in PBS is added to each well of the plate and plates are incubated for an additional 5 h at 37°C， 5% CO2， and 95% humidity. Plates are read on a Synergy2 reader using an excitation of 540 nm and an emission of 600 nm. Data are analyzed using Prism softwareto calculate IC50 values.[1-4] |
| 动物实验 | Briefly， 5×106 to 10×106 tumor cells in a 1:1 Matrigel mix (0.2 mL total volume) are injected subcutaneously into the right hind flank of female NIH nude rats. After tumors reach a desired size of approximately 300 mm3， animals are randomized into groups of 8 for efficacy studies. Drugs (LY3009120 or PLX4032) are administered orally (gavage) in 0.6-mL volume of vehicle with the dose schedules. Tumor growth and body weight are monitored over time to evaluate efficacy and signs of toxicity.[1-4] |
| 数据来源文献 | [1]. Vakana E， et al. LY3009120， a panRAF inhibitor， has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer. Oncotarget. 2017 Feb 7;8(6):9251-9266 [2]. Chen SH， et al. Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120. Cancer Discov. 2016 Mar;6(3):300-15 [3]. Peng SB， et al. Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers. Cancer Cell. 2015 Sep 14;28(3):384-98 [4]. Henry JR， et al. Discovery of 1-(3，3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2，3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a pan-RAF inhibitor with minimal paradoxical activation and activity against BRAF or RAS mutant tumo |
| 单位 | 瓶 |
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验相关实验
/content/abstract/206/10/2235 【内容简评】 Biron领导的研究组证实:NK细胞在没有细胞毒性时，激活性Ly49H受体能促进其增殖。增殖的NK细胞通过调节IL-10的产生及随后抑制具有免疫病理性的CD8T细胞，而达到调节被动免疫的目的。 人们已经知道NK细胞激活受体多数情况下与诱导先天性免疫有关，包括细胞毒性T淋巴细胞反应和NK细胞增殖。Biron利用MCMV感染的Ly49H & perforin单敲除或双敲除小鼠作为模型，发现NK细胞以Ly49H和IL-10依赖
删除突变的drs基因分析揭示，C末端区以及3个一致重复的N末端区都出现凋亡。Caspase-12、Caspase –9以及Caspase-3都继续被drs激活，Caspase--3,和Caspase-9的抑制剂都抑制drs引起的凋亡。在凋亡过程中没有看到因drs引起线粒体细胞色素C释放到细胞质去，这表明线粒体途径不是drs介导的凋亡，而且，研究人员发现，Drs蛋白能与定位在内质网的凋亡蛋白ASY/Nogo-B/RTN-x(S)结合，并且这些基因共同表达增加了凋亡的效果。这项研究结果提示，由ASY
Isolation Kit CD5(Ly-1) MicroBeadsCD8a(Ly-2) MicroBeadsCD8a+ T Cell Isolation Kit CD25 MicroBead KitCD62L(L-selectin) MicroBeadsAnti-MHC class II MicroBeadsCD4-FITC/PE/APCCD8a-FITC/PE/APCCD25-PECD62L-FITC/PE/APCCD90-FITC/PE/APC细胞因子分泌细胞Mouse IFN-r Secretion
技术资料暂无技术资料 索取技术资料
IL1800 LY-3009120 抑制剂/拮抗剂/激动剂 索莱宝
￥376 - 3990
